English
  • head_banner_01

He aha ka BPC-157

  • Inoa piha:Puʻupuʻu hoʻomalu kino-157, apentadecapeptide (15-amino acid peptide)i hoʻokaʻawale mua ʻia mai ka wai ʻōpū o ke kanaka.

  • ʻO ka pūnāwai amino acid:Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, kaumaha molekala ≈ 1419.55 Da.

  • Ke hoʻohālikelike ʻia me nā peptide ʻē aʻe he nui, ʻoi aku ka paʻa o ka BPC-157 i ka wai a me ka wai o ka ʻōpū, kahi e hiki ai i ka hoʻokele waha a i ʻole ka ʻōpū.

Nā Hana Hana

  1. ʻO ka Angiogenesis / Hoʻihoʻi ʻana i ka Circulatory

    • HoʻoponoponoVEGFR-2hōʻike, paipai i ka hoʻokumu ʻana o nā moku koko hou.

    • Ho'ā i kaAlanui Src–Caveolin-1–eNOS, alakaʻi i ka hoʻokuʻu nitric oxide (NO), vasodilation, a hoʻomaikaʻi i ka hana vascular.

  2. Anti-inflammatory & Antioxidant

    • Hoʻohaʻahaʻa i nā cytokine pro-inflammatory e like meIL-6aTNF-α.

    • Hoʻemi i ka hana ʻana o nā ʻano oxygen reactive (ROS), pale i nā cell mai ke kaumaha oxidative.

  3. Hoʻoponopono Tissue

    • Hoʻoikaika i ka hoʻihoʻi ʻana a me ka hana i ka tendon, ligament, a me nā ʻano hōʻeha ʻeha.

    • Hāʻawi i ka neuroprotection i nā ʻano hōʻeha ʻeha o ka ʻōnaehana nerve (spinal cord compression, cerebral ischemia-reperfusion), e hōʻemi ana i ka make neuronal a me ka hoʻomaikaʻi ʻana i ka hoʻihoʻi ʻana o ka motor/sensory.

  4. Ka hooponopono ana i ke kani o ke koko

    • Hōʻike nā haʻawina ex vivo vascular i ka BPC-157 e hoʻoulu i ka vasorelaxation, hilinaʻi i ka endothelium paʻa a me nā ala NO.

Animal & In Vitro Comparative Data

ʻAno hoʻokolohua Ke kumu hoʻohālike / kaʻina hana ʻAi / hoʻokele Manao Nā Hualoaʻa Nui ʻIkepili Hoʻohālikelike
Vasodilation (aorta iole, ex vivo) Phenylephrine-precontracted aortic apo BPC-157 a hiki i100 μg/ml ʻAʻohe BPC-157 ʻO ka hoʻomaha ʻana ~37.6 ± 5.7% Hoemi i10.0 ± 5.1% / 12.3 ± 2.3%me NOS mea hoʻopaneʻe (L-NAME) a ​​i ʻole NO scavenger (Hb)
Endothelial cell assay (HUVEC) moʻomeheu HUVEC 1 μg/ml Manaʻo ʻole ʻia ↑ ʻAʻole hana (1.35-papa); ↑ ka neʻe ʻana o ke kelepona Hoʻopau ʻia ka neʻe ʻana me Hb
kŘkohu lala Ischemic (iole) ʻO ka ischemia ma hope 10 μg/kg/lā (ip) ʻAʻohe lāʻau lapaʻau ʻOi aku ka wikiwiki o ke kahe koko, ↑ angiogenesis Lapaʻau > Manaʻo
Hoʻopiʻi ʻana i ke kuamoʻo (iole) ʻO ka hoʻopaʻa ʻana i ke kuamoʻo Sacrococcygeal Hoʻokahi ip injection 10 min ma hope o ka ʻeha Pūʻulu mālama ʻole ʻia ʻO ka hoʻihoʻi hou ʻana o ka neurological a me ka hoʻolālā Ua hoʻomau ka hui hoʻomalu i ka paraplegic
Hoʻohālike Hepatotoxicity (CCl₄ / waiʻona) ʻO ka ʻeha o ka ate i hoʻokomo ʻia i ke kemika 1 µg a i ʻole 10 ng/kg (ip / waha) Hana ʻole ʻia ↓ AST/ALT, hōʻemi ʻia ka necrosis Ua hōʻike ka pūʻulu hoʻomalu i ka ʻeha o ka ate
Haʻawina ʻona ʻIole, lapiti, ʻīlio He nui nā dosis / ala Nā mana placebo ʻAʻohe mea ʻona nui, ʻaʻohe LD₅₀ i ʻike ʻia Ua ʻae maikaʻi ʻia ʻoiai ma nā ʻano kiʻekiʻe

Haʻawina kanaka

  • Moʻo hihia: Intra-articular injection o BPC-157 i nā maʻi 12 me ka ʻeha kuli → 11 hōʻike i ka hoʻomaha ʻeha nui. Nā palena: ʻaʻohe pūʻulu mana, ʻaʻohe makapō, nā hopena kumuhana.

  • ʻO ka hoʻokolohua lapaʻau: Ua mālama ʻia kahi haʻawina palekana a me ka pharmacokinetic Phase I (NCT02637284) ma 42 mau mea manawaleʻa olakino, akā ʻaʻole i paʻi ʻia nā hopena.

I kēia manawa,ʻaʻohe kiʻekiʻe kiʻekiʻe kiʻekiʻe randomized controlled trials (RCTs)loaʻa e hōʻoia i ka pono lapaʻau a me ka palekana.

Palekana & Pilikia

  • ʻO ka angiogenesis: Pōmaikaʻi no ka ho'ōla ʻana, akā hiki ke hoʻoikaika i ka manaʻo o ka maʻi maʻi maʻi maʻi.

  • Dose & Administration: Pono i nā holoholona ma nā haʻahaʻa haʻahaʻa loa (ng–µg/kg), akā ʻaʻole i wehewehe ʻia ka nui o ke kanaka a me ke ala.

  • Hoʻohana lōʻihi: ʻAʻohe ʻikepili koʻikoʻi no ka wā lōʻihi; ʻo ka hapa nui o nā haʻawina he wā pōkole.

  • Kūlana hoʻoponopono: ʻAʻole i ʻae ʻia ma ke ʻano he lāʻau lapaʻau ma ka hapa nui o nā ʻāina; hoʻokaʻawale ʻia ma ke ʻano hemea kapuna WADA (World Anti-Doping Agency).

Nā ʻike hoʻohālikelike a me nā palena

Hoʻohālikelike Nā ikaika Nā palena
Holoholona vs Kanaka Nā hopena maikaʻi mau i nā holoholona (tendon, nerve, hoʻoponopono i ka ate, angiogenesis) He liʻiliʻi ka hōʻike kanaka, ʻaʻole i hoʻomalu ʻia, a nele i ka hahai ʻana i ka wā lōʻihi
Laulā kaʻina Pono i nā haʻahaʻa haʻahaʻa loa i nā holoholona (ng–µg/kg; µg/ml in vitro) ʻAʻole ʻike ʻia ka dosing kanaka palekana/maikaʻi
Hoʻomaka ka hana ʻO ka hoʻoponopono mua ʻana ma hope o ka ʻeha (e laʻa, 10 min ma hope o ka hōʻeha ʻana i ke kuamoʻo) e hoʻōla ikaika ʻAʻole maopopo ka hiki ʻana o ke kino o ia manawa
Kaʻawaʻawa ʻAʻole ʻike ʻia ka nui lethal a i ʻole nā ​​hopena koʻikoʻi i nā ʻano holoholona he nui ʻAʻole i hoʻāʻo ʻia ka ʻona lōʻihi, ka carcinogenicity, a me ka palekana hānau

Ka hopena

  • Hōʻike ka BPC-157 i nā hopena hoʻoulu hou a me ka pale i nā hiʻohiʻona holoholona a me nā cell: angiogenesis, anti-inflammation, hoʻoponopono kino, neuroprotection, a me ka hepatoprotection.

  • He palena loa nā hōʻike kanaka, me ka loaʻa ʻole o ka ʻikepili hoʻokolohua lapaʻau ikaika.

  • Eia hou akui hoʻolālā maikaʻi ʻia nā hoʻāʻo hoʻokele randomizedkoi ʻia e hoʻokumu i ka pono, palekana, ka hoʻopaʻa ʻana maikaʻi loa, a me nā ala hoʻokele i nā kānaka.

Ka manawa hoʻouna: Sep-23-2025
E kaomi i ke komo no ka huli ʻana a i ʻole ESC e pani